Table 2 Incidence rates and risks of AVF/AVG dysfunction in SLE and non-SLE patients.

Time period	SLE patients			Non-SLE patients (reference)			Crude		Competing risk
Time period	No. of events	Person-years	Incidence rate^a	No. of events	Person-years	Incidence rate^a	HR (95% CI)	P	SHR (95% CI)	P
Overall period	924	3927	23.53	2589	11,950	21.66	1.07 (0.99, 1.16)	0.068	1.09 (1.00, 1.17)	0.027*
Within 90 days	206	313	65.87	580	937	61.90	1.06 (0.91, 1.25)	0.446	1.06 (0.91, 1.25)	0.442
Within 180 days	347	573	60.52	1009	1720	58.66	1.03 (0.91, 1.17)	0.616	1.04 (0.92, 1.17)	0.572
First year	483	1027	47.05	1434	3071	46.69	1.01 (0.91, 1.12)	0.871	1.01 (0.92, 1.12)	0.782
> 1 year	441	2900	15.21	1155	8879	13.01	1.15 (1.02, 1.29)	0.011	1.16 (1.04, 1.29)	0.007*
1–5 years	332	1973	16.83	910	5824	15.62	1.08 (0.95, 1.22)	0.255	1.09 (0.96, 1.24)	0.174
Within 5 years	815	3000	27.17	2344	8896	26.35	1.03 (0.96, 1.12)	0.4	1.05 (0.97, 1.14)	0.222
5–10 years	100	839.7	11.91	218	2692	8.10	1.47 (1.16, 1.86)	0.001	1.42 (1.12, 1.79)	0.003*
1–10 years	432	2813	15.36	1128	8516	13.25	1.15 (1.03, 1.28)	0.015	1.16 (1.04, 1.29)	0.007*
> 10 years	9	87.7	10.26	27	363	7.45	1.37 (0.64, 2.91)	0.416	1.34 (0.63, 2.85)	0.450

AVF arteriovenous fistula, AVG arteriovenous graft, SLE systemic lupus erythematosus, HR hazard ratio, SHR subdistribution hazard ratio, CI confidence interval.
^aPer 100 person-years.

Quick links

Search